Curaleaf (OTCMKTS:CURLF – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Curaleaf to related companies based on the strength of its institutional ownership, dividends, risk, earnings, analyst recommendations, profitability and valuation.
Institutional and Insider Ownership
0.0% of Curaleaf shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Curaleaf has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Curaleaf’s peers have a beta of 2.55, suggesting that their average share price is 155% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Curaleaf and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 1 | 2 | 1 | 3.00 |
| Curaleaf Competitors | 4251 | 10479 | 18202 | 824 | 2.46 |
Curaleaf currently has a consensus price target of $6.00, suggesting a potential downside of 27.45%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.65%. Given Curaleaf’s peers higher possible upside, analysts clearly believe Curaleaf has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Curaleaf and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | -$231.07 million | -63.62 |
| Curaleaf Competitors | $1.87 billion | $138.21 million | 10.70 |
Curaleaf’s peers have higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Curaleaf and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -2.62% | -0.88% | -0.26% |
| Curaleaf Competitors | -278.23% | -150.07% | -21.87% |
Summary
Curaleaf peers beat Curaleaf on 8 of the 13 factors compared.
Curaleaf Company Profile
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
